Bioclinical Parameters Driving Decision-Making of Subsequent Lines of Treatment in Metastatic Castration-Resistant Prostate Cancer

Table 1

Patients’ features.

Clinical trial	Median age	Range	≥75 years	PS 2	Visceral metastases
TROPIC	68	62–73	18%	7%	25%
COU-AA-301	69	42–95	28%	10%	11% (liver metastases)
AFFIRM	69	41–92	25%	8.5%	23.2%